+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hypertrophic Cardiomyopathy Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4896254
  • Report
  • January 2020
  • Region: Global
  • 111 pages
  • Mordor Intelligence
UP TO OFF
until Mar 31st 2020
1 of 4

FEATURED COMPANIES

  • Astra Zeneca Plc
  • Bayer AG
  • Gilead Sciences, Inc
  • Merck & Co., Inc
  • Mylan N.V.
  • Novartis AG
  • MORE
Market Overview

Hypertrophic cardiomyopathy (HCM) is a genetic heart muscle disease caused by a mutation in sarcomere protein genes which encodes for the contractile machinery of the heart which is characterized by an increase in left ventricular wall thickness which causes left ventricular outflow obstruction, diastolic dysfunction, myocardial ischemia, and mitral regurgitation. Symptoms of the hypertrophic cardiomyopathy are fatigue, dyspnea, chest pain, palpitations, and syncope. In the year 2015, Out of the 17 million premature deaths who are under the age of 70 are due to noncommunicable diseases i.e 82% in low- and middle-income countries and 37% are caused by cardiovascular disease. According to World Health Organization (WHO), an estimated of 17.9 million people died from cardiovascular diseases in the year 2016, which accounts 31% of all global deaths. An increase in obese and sedentary lifestyle population, increasing cases of cardiac diseases are the major driving factors in the hypertrophic cardiomyopathy therapeutics market.

Scope of the Report

Hypertrophic cardiomyopathy is a genetic heart muscle disease caused by a mutation in sarcomere protein genes which encodes for the contractile machinery of the heart. Hypertrophic cardiomyopathy therapeutics are segmented by Drug Class (Antiarrhythmic Agents, Anticoagulants, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Others) and Geography.

Key Market Trends

Calcium Channel Blockers Segment is Expected to Hold a Major Market Share in Hypertrophic Cardiomyopathy Therapeutics Market
  • Calcium channel blockers or calcium channel antagonists or calcium antagonists are most commonly used as antihypertensive drugs that act by reducing the amount of calcium that goes into the cardiac muscle cells and cause them to relax.
  • Calcium channel blockers are used to alter the heart rate, reduce chest pain, and to prevent cerebral vasospasm more effective compared to beta-blockers in the treatment of cardiovascular disorders.
  • A rise in the geriatric population and obesity are the major factors driving the calcium Channel Blockers market.
North America is Expected to Dominate the Market and Expected to do Same in the Forecast Period

North America expected to hold significant market share in the global hypertrophic cardiomyopathy (HCM) market due to the rising prevalence of congestive heart failure, sedentary lifestyles of individuals in the united states. As per The Centers for Disease Control and Prevention (CDC), more than five million people are suffering from heart failure diseases in the United States, and about half of the affected population die within five years of diagnosis. Moreover, the existence of a developed healthcare care system and affordable reimbursement policies for the treatment of cardiovascular diseases are anticipated to positively reinforce the growth.

Competitive Landscape

The Hypertrophic Cardiomyopathy Therapeutics Market is moderately consolidated competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Sanofi S.A., Astra Zeneca Plc, Pfizer Inc, ADVANI PHARMA Corp (Concordia Healthcare Corp), Gilead Sciences Inc, Merck & Co., Inc, Teva Pharmaceutical Industries Ltd, Novartis AG, Mylan N.V., Bayer AG.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • Report customization as per the client's requirements.
  • 3 months of analyst support.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Astra Zeneca Plc
  • Bayer AG
  • Gilead Sciences, Inc
  • Merck & Co., Inc
  • Mylan N.V.
  • Novartis AG
  • MORE
1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Obese and Sedentary Lifestyle Population
4.2.2 New Product Development for Targeted Cardiac Disorders
4.3 Market Restraints
4.3.1 Technological Advancement in Devices
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Drug Class
5.1.1 Antiarrhythmic Agents
5.1.2 Anticoagulants
5.1.3 Beta Adrenergic Blocking Agents
5.1.4 Calcium Channel Blockers
5.1.5 Others
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East and Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East and Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Astra Zeneca Plc
6.1.2 ADVANZ PHARMA Corp (Concordia Healthcare Corp)
6.1.3 Bayer AG
6.1.4 Gilead Sciences, Inc
6.1.5 Merck & Co., Inc
6.1.6 Mylan N.V.
6.1.7 Novartis AG
6.1.8 Pfizer, Inc
6.1.9 Sanofi S.A.
6.1.10 Teva Pharmaceutical Industries Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Astra Zeneca Plc
  • ADVANZ PHARMA Corp (Concordia Healthcare Corp)
  • Bayer AG
  • Gilead Sciences, Inc
  • Merck & Co., Inc
  • Mylan N.V.
  • Novartis AG
  • Pfizer, Inc
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd
Note: Product cover images may vary from those shown
Adroll
adroll